TLDR Pioglitazone may help treat lichen planopilaris, but more research is needed.
This study evaluated the efficacy of pioglitazone, a PPAR-γ agonist, in treating lichen planopilaris (LPP) in 22 female patients who were refractory to multiple prior therapies. The results showed that 72.7% of patients experienced marked improvement in symptoms, inflammation, and disease progression, with 27.3% noting new hair regrowth. However, side effects such as lower-extremity edema and weight gain were reported. The study concluded that PPAR-γ agonists could be a viable treatment option for LPP, targeting its inflammatory stages, but emphasized the need for a prospective, double-blind, randomized trial to confirm these findings.
105 citations
,
December 2009 in “Archives of dermatology” A specific drug can help treat Lichen Planopilaris, a condition causing permanent hair loss.
45 citations
,
April 2019 in “International Immunology” The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
January 2025 in “Indian Journal of Dermatology” Frontal fibrosing alopecia is a challenging hair loss condition with no known cause or definitive treatment.
80 citations
,
April 2018 in “Trends in Molecular Medicine” Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.
4 citations
,
May 2012 in “Journal of Investigative Dermatology” The symposium concluded that a specific lipid might cause hair loss, inflammation is a key factor, and stem cells in bald scalps aren't working right, suggesting new treatment targets.
38 citations
,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
July 2022 in “Research Square (Research Square)” Lower PPARγ levels and specific gene variations are linked to more severe Frontal Fibrosing Alopecia.